Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia

Methods Mol Biol. 2014:1160:115-24. doi: 10.1007/978-1-4939-0733-5_11.

Abstract

The BCR-ABL1 fusion gene, the causative lesion of chronic myeloid leukemia (CML) in >95 % of newly presenting patients, offers both a therapeutic and diagnostic target. Reverse-transcription quantitative polymerase chain reaction technology (RT-qPCR), utilizing primer-probe combinations directed to exons flanking the breakpoint junctional region, offers very high levels of both specificity and sensitivity, in a scalable, robust, and cost-effective assay.

MeSH terms

  • Cell Separation
  • Cloning, Molecular
  • DNA, Complementary / biosynthesis
  • DNA, Complementary / genetics
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukocytes / metabolism
  • Leukocytes / pathology
  • RNA, Messenger / analysis
  • RNA, Messenger / genetics
  • Reverse Transcriptase Polymerase Chain Reaction / methods*

Substances

  • DNA, Complementary
  • RNA, Messenger
  • Fusion Proteins, bcr-abl